1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
6 citations
,
January 2012 in “Journal of Biomedicine and Biotechnology” Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
2 citations
,
January 2025 in “Journal of Oncology Pharmacy Practice” Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology” July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
12 citations
,
May 2020 in “Dermatology and therapy” A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
February 2010 in “Journal of The American Academy of Dermatology” Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
3 citations
,
November 2023 in “The Journal of Dermatology”
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.